Instytut Psychiatrii i Neurologii
Instytut Psychiatrii i Neurologii
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2007-3.3-3 | Award Amount: 4.01M | Year: 2009
AMPHORA is a Europe wide project involving researches and research institutions from 14 European countries, and counterparts and organizations from all 27 Member States, that will provide new scientific evidence for the best public health measures to reduce the harm done by alcohol through addressing social and cultural determinants, marketing and advertising, taxes and pricing, availability and access, early diagnosis and treatment of disease, interventions in drinking environments, and safer untaxed alcohol products. Cost effectiveness analyses will be undertaken in multiple settings, geographical regions, and for different gender and age groups to guide integrated policy making to reduce the harm done by alcohol. Using time series analysis, longitudinal intervention research, policy mapping, cost effectiveness analyses, and other policy relevant research methodologies, recent and current alcohol policy changes will be evaluated throughout European Member States. Current alcohol policy related infrastructures will be documented and their impact on effective policy development and implementation analyzed. The interaction between social and cultural determinants of alcohol policy and policy and preventive measures will be studied to determine the extent to which the implementation and impact of effective alcohol policies is culturally determined. Methodologies will be developed to allow tools for benchmarking and comparative analysis at the European level, advancing the state of the art in alcohol policy research and enhancing cooperation between researchers in Europe and other geographic regions to promote integration and excellence of European research in alcohol policy. AMPHORA will provide the evidence base to inform policy and decision makers at European, national and local levels to implement effective interventions to reduce the harm done by alcohol throughout a wide range of policies implemented in different sectors and settings.
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: SSH-2010-3.2-1 | Award Amount: 10.21M | Year: 2011
ALICE RAP is a Europe wide project of 43 partner research institutions involving 107 researchers from 25 European countries providing 1000 months of a plurality of scientific endeavour to analyse the place and challenges of addictions and lifestyles to the cohesion, organization and functioning of contemporary European society. Through integrated multidisciplinary research, a wide range of factors will be studied through a foresight approach to inform a redesign of effective addictions governance. Ownership will be described by an historical study of addiction through the ages, an analysis of public and private stakeholder views, and through image analyses, of professional and citizenship views. A study of how addictions are classified and defined will be followed by estimates of their health, social and economic impact. Determinants of addiction will be investigated through a coordinated and cohesive social, economic and biological analysis of initiation, transition into problem use and transition into and out of dependence. The business of addiction will be analyzed through studies of revenues, profits and participants in legal and illegal trade, the impact of suppliers on addictive substance use and behaviours, and analyses of webs of influence on policy responses. Addictions governance will be studied by describing the views and forces that determine the ways societies steer themselves and by stock taking of present governance practices to old and emerging addictions. Youth as customers will be analyzed through considering the impacts of new technologies on promoting and mitigating use, by studying the interrelations of culture and biology, and by determining features that promote resilience and nudge young people to reduce problematic use. The programme itself will be professionally managed from a partnership perspective to promote a coordinated and integrated approach to the high volume of research and its policy implications.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-17-2014 | Award Amount: 5.99M | Year: 2015
Every year, 1.3 million Europeans have a stroke and one million ultimately die of stroke. One third of stroke patients remain dependent on the help of others. The annual costs for stroke care in Europe are estimated at 64.1 billion. Stroke incidence increases almost exponentially with age, and the personal, societal, and economic burden of stroke is therefore largely driven by its frequent occurrence in the elderly. The elderly have been strongly underrepresented in previous stroke trials and treatment guidelines have no recommendations specific to this important group. Elderly patients are at the highest risk of complications after stroke, such as infections, fever, and dysphagia. These complications are strongly and independently associated with a higher risk of death or dependency. We will perform a pragmatic, randomised, open clinical trial with blinded outcome assessment in 3800 patients with acute stroke aged 66 years or older, to assess whether pharmacological prevention of infections and fever, and early management of dysphagia, will reduce the risk of death, poor functional outcome, and poor quality of life, and lead to reductions in the costs of stroke care throughout Europe. Patients will be randomised using a factorial design to preventive treatment for 4 days with ceftriaxone, paracetamol, and/or metoclopramide, or to standard care alone. The primary outcome is functional outcome at 3 months, assessed with the modified Rankin Scale (mRS), and analysed with ordinal logistic regression. The study will have 90% power to detect a statistically significant shift towards a favourable outcome, assuming a 5% absolute increase in the proportion of patients with a good outcome (mRS 0 to 2) in the intervention group, compared with controls. This simple, safe, and generally available treatment strategy has the potential to lead to an annual reduction of over 25 000 elderly Europeans being dead or dependent as a result of stroke, at very low costs.
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2011.2.4.2-1 | Award Amount: 14.96M | Year: 2012
The consortium led by UKER and EuroHYP, the European Stroke Research Network for Hypothermia, proposes a large, multicentre clinical trial which will assess mild hypothermia as a novel treatment for ischemic stroke. Stroke is the second cause of death world-wide and the second cause of lost disability-adjusted life years in high-income countries. Stroke incidence rises exponentially with age, so its social and economic burden will grow with the ageing of the European population. Current treatment options for the 80 to 85% of all strokes due to cerebral ischaemia - around. 900,000 events in Europe every year, or one every 40 seconds - are extremely limited. Systematic review of experimental studies suggests that hypothermia is the most promising intervention identified to date. Therapeutic cooling is effective in reducing ischaemic brain injury following cardiac arrest, and hypothermia is therefore considered by experts the most promising treatment for patients with acute ischaemic stroke, next to reperfusion strategies. The EuroHYP-1 trial is a pan-European, open, randomised, phase III clinical trial which will assess the benefit or harm of therapeutic cooling in 1500 awake adult patients with acute ischaemic stroke. In addition to efficacy and safety, the economic impact of therapeutic hypothermia will be assessed, along with several sub-studies involving imaging, ultrasound, and biomarker methods. The investigators involved in the EuroHYP-1 consortium are leading European experts in statistical design and analysis, therapeutic hypothermia, imaging, health economics, ultrasound, biomarkers, and trial execution (implementation and monitoring). Moreover in addition to these academic experts the consortium also involves European patient and family advocacy groups and small and medium-size enterprises, and the joint endeavours of this extended team will ensure the successful enrolment of patients at eighty hospitals across 25 countries in Europe.
Agency: European Commission | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2012-ITN | Award Amount: 3.69M | Year: 2013
MARATONE is a Marie Curie Initial Training Network proposal that directly addresses the need for high-level training and career pathways in mental health to increase the inter-sectorial and trans-national employability of young scientists in the academic, public and private sectors to meet the enormous challenge of the 2009 EU Parliament Resolution on Mental Health. The Resolution set out recommendations for a comprehensive and integrated mental health strategy for Europe. MARATONE is designed to address the biggest challenge to implementing this ambitious strategy: the lack of training for career pathways for young scientists in multidisciplinary mental health research. MARATONE is built on the innovative theoretical premise of horizontal epidemiology, the view that psychosocial difficulties associated with mental health disorders are not exclusively determined by the diagnosis of the particular disorder in a vertical, silo-like pattern but horizontally in a manner that reflects commonalities in the lived experience of people with diverse mental health problems. Grounded in this theoretical foundation, MARATONEs multidisciplinary network of partners will collaboratively develop methodologies for measuring the individual and social impact of mental health disorders, so as to create strategies for the social and private sector responses to mental ill health in the form of health promotion and prevention programmes, and at the national level, strategies for human rights protections in policies and programming. The consortium will provide young researchers with scientific expertise in mental health, as well as basic technical and communication skills, including research development and management, international human rights commitments, and commercial exploitation and dissemination.
Agency: European Commission | Branch: FP7 | Program: CSA-CA | Phase: HEALTH-2009-2.2.1-5 | Award Amount: 1.68M | Year: 2010
The overall prevalence of brain disorders both neurological and psychiatric is very high in Europe. Although it is well known that the burden and costs of these disorders are high, there is evidence that the overall, personal, social and economic costs of brain disorders have been underestimated because of the lack of valid and reliable information regarding the full range of psychosocial difficulties that actually shape the lived experience of persons with these disorders and affect their quality of life. Current European data on psychosocial difficulties are derived from the diagnostic criteria of each disorder and so take the form of narrow information silos that are neither comprehensive nor comparable across disorders. Distinct information silos means that treatment planning, treatment evaluation and outcome assessment ignores commonalities of psychosocial consequences across disorders, undermining treatment efficiency and effectiveness, and ultimately increasing the costs of health and social care provision. The coordination action called PARADISE has the general objective of coordinating the development of a comprehensive and cross-cutting or horizontal epidemiology of psychosocial difficulties associated with brain disorders. Since a horizontal epidemiology accounts for the psychosocial difficulties that are actually experienced by people with brain disorders, independently of the brain disorder associated with them, it concentrates on what is more relevant to the lives of people with brain disorders. This leads to more effective intervention planning and management, and therefore to improved quality of life along the continuum of care, in the community, and across the life span. PARADISE coordinates the existing expertise in partners from eight European countries in relation to research literature, data documentation and analysis strategies for a representative range of brain disorders. These disorders are dementia, depression, epilepsy, migraine, multiple sclerosis, Parkinsons Disease, schizophrenia, stroke and substance use disorders. PARADISE will pave the way to future investigations that more meaningfully track the trajectories of psychosocial difficulties of brain disorders.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.3.1-1 | Award Amount: 6.39M | Year: 2014
Mental disorders affect 38.2% of the EU population. For reducing the associated burden, countries across Europe engage in costly re-organizations of mental health care systems. Reforms focus on one controversial core question: Should systems be functional or integrated? In functional systems, separate staff in different services are in charge of in- and out-patient care (to enhance specialization). In integrated systems, the same staff are responsible across services (to strengthen co-ordination and avoid fragmentation). So far, there is no sound research evidence to inform the debate and far reaching policy decisions. Integrated and functional systems co-exist in some countries. This provides the unique chance to compare the effectiveness of the two systems independently of country specific contexts. We will conduct a large-scale comparison in countries with different traditions, levels of service provision and funding systems of mental health care (Belgium, Germany, Italy, Poland, United Kingdom). We will work as a multi-disciplinary team (psychiatrists, psychologists, nurses, sociologists, public health experts, health economists) and prospectively follow-up more than 5000 patients with major mental disorders over a 9 month period. Across countries, we will compare the effectiveness and cost-effectiveness for clinical and social outcomes (including quality of life), patients health and social needs, safety and quality of care of patients in the two systems. We will also establish how patients and clinicians experience the advantages and limitations of each system, and identify the policies and legislative frameworks determining practice in the two systems. We will produce guidelines for policies specifying in what context and for which patient groups (e.g. older age) functional or integrated systems are preferable, and disseminate these widely (to governments, scientific societies, professional bodies, users and carers organizations).